The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.
Patients included will have overactive bladder symptoms refractory to medical therapy. Other causes of overactive bladder symptoms including urogenital prolapse and recurrent urinary tract infections were excluded. None of the patients will be under anticoagulant therapy or drugs interfering with neuromuscular transmission. The study was approved by the local ethical committee and patients gave their informed consent. Patients will be informed about the possible need for intermittent catheterization after BoNT/A treatment. As outcome measures we assessed clinical and urodynamic variables.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
One treatment, 200 U vials diluted in 20 ml normal saline
As primary outcome measures, patients attended for clinical evaluation (daily voiding diary an QoL questionnaire).
Time frame: One, three and five months after intravesical treatment
Urodynamic assessment, and samples were obtained for urinalysis and culture.
Time frame: One, three and five months follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.